The first week of May was red for 3 days, with a weekly increase of 1.92%; the first week of June was red for 4 days, with a weekly increase of 1.13%. Whether the real increase lies in the changes in the second week, which is also an important week for the announcement of major external events. The biggest difference from May is that the external financial market has begun to "highs", which will inevitably drive A-shares to rise. The key is whether institutional funds "really go long". What the market lacks now is confidence and the intervention of real money. Since the beginning of this year, the market has been mainly local, and the market for a comprehensive rebound has never arrived, so investors are in a two-level state: "Those who make money make a fortune in silence, and those who lose money are addicted to eating noodles!"
Ride bulls and see bears to findInnovative drugs have transitioned from the policy stimulus stage, gradually triggering industrial transformation. The policy trend is to select the best on the supply side and support innovative drugs to go overseas. In terms of cooperation direction, domestic pharmaceutical company BD has begun to shift from inward introduction to external authorization, and China's innovative drugs have changed from overseas importers to foreign exporters. After nearly 10 years of rapid development of innovative drugs in China, it is standing at a critical turning point from quantitative change to qualitative change, with a broad prospect. In the medium and long term, the industry has been operating to a high-quality development stage of R&D upgrade, innovation and truth-seeking, and international integration. Biotech's performance has gradually moved towards a profit cycle, the existing business of traditional Pharma companies has been gradually cleared, and the innovation pipeline has entered a period of fulfillment. With the continued implementation of support policies, the sector is expected to usher in investment opportunities, both performance and valuation have been improved.
The three major indexes opened higher collectively. The stocks in the two markets opened more red and fell less. In terms of theme sectors, sports, CXO, weight loss drugs and other sectors performed strongly, while precious metals, scarce resources, white goods and other sectors performed poorly. Innovative drug concept stocks continue to be active, Changshan Pharmaceutical continues to hit a record high, Ruizhi Pharmaceutical rose by more than 10%, Anglikang, Zhongsheng Pharmaceutical and other stocks hit the daily limit, Beilu Pharmaceutical and Yuekang Pharmaceutical rose by more than 5%, the pharmaceutical market will usher in a continuous recovery, and structural opportunities still exist. From the perspective of short-term and medium- and long-term certain growth, we are optimistic that the innovative drug industry chain will continue to perform well this year.
The concept of stablecoin has been active repeatedly, Jinshi Technology has gone out of five consecutive boards, Chu Tianlong, Dongxin Heping and other stocks hit the daily limit, Qitian Technology, Hailian Jinhuichuang and others followed suit. On June 7, the first stablecoin stock Circle rose 29.4% the day after listing, closing at US$107.7 per share. Military industrial stocks fluctuated and rose, AVIC Shenfei hit the daily limit, Maisinlin, Lijun shares and others rose by more than 5%. Indonesia's deputy defense minister said that the performance of China's J-10 fighter jets in the India-Pakistan conflict is one of the important factors for Indonesia to consider this model.
Shanghai Index opened high and closed high on Monday, and once stood above 3400 points during the session, showing a new high. However, there are more traps in the first line of 3400 points, and there is still no increase in volume here. Pay attention to the changes in the market trend. This week is likely to be a battle. Starting on June 10, China and the United States will hold talks in the UK. This is the second economic and trade consultation held by the two sides since the outbreak of the US-China tariff war. The content focuses on issues such as tariffs, technology and rare earths. Considering that the tariff issues have a great impact on external demand, it is recommended to pay attention to the results of the consultation. Some varieties have a high rebound rate and still have the value of selling insurance. In the afternoon, pay attention to whether the Shanghai Composite Index can stabilize above 3400 points.
The ChiNext Index rose nearly 2% during the session on Monday. The difference between this rebound and the previous one is that the market has a general rebound. The decline stocks were once less than 1,000, which was a situation that did not occur in the four consecutive positive moments last week. Starting in June, the index fluctuated upward, and the trend was still relatively strong, but the trading volume has not increased significantly at present, and there is no obvious change in the driving force. Therefore, we maintain our previous view that the index will remain unchanged, that is, the probability of the index maintaining range fluctuations in June is relatively high. In the afternoon, pay attention to whether the ChiNext Index can stabilize above 2070 points.
Midday news:
1.The People's Bank of China carried out a 173.8 billion yuan 7-day reverse repurchase operation today, with the operating interest rate remaining flat at 1.40%. No reverse repurchase expires today
2.-->
